bpc 157 human clinical data dosing BPC-157 Dosage Guide: Protocols & Safety 2026 BPC-157 Dosage and Protocol: An

(ii) With respect to NDCs that were sold or marketed during the applicable calendar quarter and lack manufacturer-reported ASP units for the applicable calendar quarter, and NDCs that were sold or marketed during the applicable calendar quarter and for which respective NDCs have positive manufacturer-reported units by, apportion rebate amounts as follows: (A) Solely for purposes of the calculation determined under this paragraph (c)(2)(ii) of this section, assign to NDCs that were sold or marketed during the applicable calendar quarter and lack manufacturer-reported ASP units for the applicable calendar quarter the number of ASP units that is equal to the lowest positive number of manufacturer reported ASP units for any NDC in the grouped billing and payment code

doi: 10.1186/s40635-023-00548-w 73

Thank you to those of you who joined us for these virtual events

The journal of headache and pain